Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy.


Journal Article

Doxorubicin-induced cardiomyopathy is not uncommon and may progress to end-stage heart failure. Treatment of this condition with heart transplantation, however, requires that the primary malignancy be deemed "cured." We present the case of a 55- year-old woman who had doxorubicin-induced cardiomyopathy and non-Hodgkin's lymphoma. The active status of her lymphoma precluded heart transplantation. She had end-stage heart failure and underwent the insertion of a left ventricular assist device as a destination therapy.

Full Text

Duke Authors

Cited Authors

  • Simsir, SA; Lin, SS; Blue, LJ; Gockerman, JP; Russell, SD; Milano, CA

Published Date

  • August 2005

Published In

Volume / Issue

  • 80 / 2

Start / End Page

  • 717 - 719

PubMed ID

  • 16039240

Pubmed Central ID

  • 16039240

Electronic International Standard Serial Number (EISSN)

  • 1552-6259

Digital Object Identifier (DOI)

  • 10.1016/j.athoracsur.2004.02.036


  • eng

Conference Location

  • Netherlands